Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy.

Abstract

Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.

• Authors: Adele D'Amico, Michela Catteruccia, Fabrizio De Benedetti, Marina Vivarelli, Manuela Colucci, Simona Cascioli, Enrico Bertini
• Journal: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society (Eur J Paediatr Neurol) Vol. 16 Issue 3 Pg. 301-3 (May 2012) ISSN: 1532-2130 [Electronic] England
• PMID: 21903431 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2011 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Immunologic Factors
• Rituximab

Topics

• Age of Onset
• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Child
• Electrophysiology
• Female
• Humans
• Immunologic Factors (therapeutic use)
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (drug therapy, physiopathology)
• Rituximab
• Young Adult